Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Sepsis is a leading cause of death in intensive care units and survivors develop prolonged immunosuppression and a high incidence of recurrent infections. No definitive therapy exists to treat sepsis and physicians rely on supportive care including antibiotics, intravenous fluids, and vasopressors. With the rising incidence of antibiotic resistant microbes, it is becoming increasingly critical to discover novel therapeutics. Sepsis-induced leukocyte dysfunction and immunosuppression is recognized as an important contributor towards increased morbidity and mortality. Pre-clinical and clinical studies show that specific cell surface inhibitory immune checkpoint receptors and ligands including PD-1, PD-L1, CTLA4, BTLA, TIM3, OX40, and 2B4 play important roles in the pathophysiology of sepsis by mediating a fine balance between host immune competency and immunosuppression. Pre-clinical studies targeting the inhibitory effects of these immune checkpoints have demonstrated reversal of leukocyte dysfunction and improved host resistance of infection. Measurement of immune checkpoint expression on peripheral blood leukocytes may serve as a means of stratifying patients to direct individualized therapy. This review focuses on advances in our understanding of the role of immune checkpoints in the host response to infections, and the potential clinical application of therapeutics targeting the inhibitory immune checkpoint pathways for the management of septic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 3×
“PD-1 is expressed on variety of leukocytes including T and B lymphocytes, monocytes, NK cells, and dendritic cells (21).”
BackgroundFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 2×
“Upon PD-1 ligation, SHP-2 dephosphorylates phosphoinositide 3kinase (PI3K) leading to inhibition of Protein Kinase B (Akt) and extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathways (Figure 1) (79, 81).”
BackgroundMolecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Long-term cognitive impairment after critical illness
Pandharipande, P. P., Girard, T. D., Jackson, J. C., Morandi, A., Thompson, J. L., Pun, B. T., Brummel, N. E., Hughes, C. G., Vasilevskis, E. E., Shintani, A. K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301372 · Cited by 2,842
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · cited 17×
“CTLA-4 (CD152) is a dimeric cell surface glycoprotein, which binds to CD80 and CD86 cell surface receptors on APCs (36).”
BackgroundInfluentialDefining trained immunity and its role in health and disease
Netea, M. G., Domínguez-Andrés, J., Barreiro, L. B., Chavakis, T., Divangahi, M., Fuchs, E., Joosten, L. A. B., van der Meer, J. W. M., Mhlanga, M. M., Mulder, W. J. M., et al. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0285-6 · Cited by 2,690
Long-term cognitive impairment and functional disability among survivors of severe sepsis.
Iwashyna, T. J., Ely, E. W., Smith, D. M., & Langa, K. M. (2010) · JAMA · doi:10.1001/jama.2010.1553 · Cited by 2,582
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · cited 10×
“Major cell surface inhibitory immune checkpoints include programmed cell death receptor-1 (PD-1), programmed cell death receptor ligand-1 (PD-L1), programmed cell death receptor ligand-2 (PD-L2), cytotoxic T lymphocyte antigen-4 (CTLA-4), B and T lymphocyte attenuator (BTLA), lymphocyte activation-gene-3 (LAG-3) and T…”
BackgroundInfluential
Cited by
Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options
Liu, D., Huang, S.-Y., Sun, J.-H., Zhang, H.-C., Cai, Q.-L., Gao, C., Li, L., Cao, J., Xu, F., Zhou, Y., et al. (2022) · Military Medical Research · doi:10.1186/s40779-022-00422-y · Cited by 607
Sepsis-Induced Immunosuppression
Torres, L. K., Pickkers, P., & van der Poll, T. (2022) · Annual Review of Physiology · doi:10.1146/annurev-physiol-061121-040214 · Cited by 355
Insight Into Regulatory T Cells in Sepsis-Associated Encephalopathy
Gao, Y.-L., Liu, Y.-C., Zhang, X., Shou, S.-T., & Chai, Y.-F. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.830784 · Cited by 11
Tang, Y.-F., Duan, Y.-J., Ge, R.-D., Lu, X., Gao, B.-Y., Guo, J.-W., & Jiang, S. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2201005 · Cited by 5
Metadata
- Authors
- McBride, M. A., Patil, T. K., Bohannon, J. K., Hernandez, A., Sherwood, E. R., & Patil, N. K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-02-03
- Volume
- 11
- Pages
- 624272-624272
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3128329360
- Cited by
- 121
- References
- 26
- FWCI
- 13.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression. https://app.cochat.ai/papers/10.3389/fimmu.2020.624272
- The paper
- McBride, M. A., Patil, T. K., Bohannon, J. K., Hernandez, A., Sherwood, E. R., & Patil, N. K. (2021). Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.624272
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.